Monitoring of Myeloid Neoplasms in the Era of Next Generation Sequencing



About this Webinar

Date: Monday, February 09, 2015

Author: Racke, Frederick K., MD, PhD.
Medical Director, Hematology/Oncology and Coagulation,
Nichols Institute
Quest Diagnostics
San Juan Capistrano, CA
Also by this Author 

Category: CE Credit, Webinar

Description: Dr. Racke discusses the incorporation of new molecular markers into the diagnostics algorithms for myeloid neoplasms, illustrates the principles of molecular monitoring and helps participants understand the benefit and pitfalls in the use of next generation sequencing.
Quest Diagnostics is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.® program. This webinar will provide 1.0 contact hour — Intermediate Level.

At the end of this webinar, participants will be able to:
- Discuss the incorporation of new molecular markers (including CALR, CSF3R, ASXL1, TET2 and DMNT3A) into the diagnostic algorithms for myeloid neoplasms
- Illustrate the principle of molecular monitoring following treatment in AML and high grade MDS
- Understand the benefits and pitfalls in the use of next-generation sequencing (NGS) for the workup of myeloid neoplasms